Shattuck Labs (NASDAQ:STTK) Insider Sells $165,424.20 in Stock

Shattuck Labs, Inc. (NASDAQ:STTK) insider Abhinav Shukla sold 23,365 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $7.08, for a total transaction of $165,424.20. Following the sale, the insider directly owned 86,380 shares of the company’s stock, valued at $611,570.40. The trade was a 21.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shattuck Labs Stock Performance

Shares of NASDAQ:STTK opened at $7.05 on Friday. The firm has a market cap of $540.59 million, a PE ratio of -11.19 and a beta of 1.05. The company has a fifty day simple moving average of $5.96 and a 200 day simple moving average of $5.27. Shattuck Labs, Inc. has a 12-month low of $0.71 and a 12-month high of $8.33.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. During the same quarter in the prior year, the company earned ($0.27) EPS. As a group, equities research analysts forecast that Shattuck Labs, Inc. will post -0.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on STTK shares. Weiss Ratings raised Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th. Wedbush increased their target price on Shattuck Labs from $8.00 to $11.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Needham & Company LLC lifted their target price on Shattuck Labs from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Wall Street Zen upgraded Shattuck Labs from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Finally, Citigroup raised Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Friday, June 5th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Shattuck Labs currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Investors Weigh In On Shattuck Labs

A number of institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in Shattuck Labs during the third quarter worth about $38,000. AQR Capital Management LLC lifted its holdings in Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after acquiring an additional 31,355 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in Shattuck Labs in the second quarter valued at approximately $44,000. Squarepoint Ops LLC acquired a new position in Shattuck Labs in the third quarter valued at approximately $46,000. Finally, Bridgeway Capital Management LLC grew its holdings in shares of Shattuck Labs by 147.5% during the second quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock valued at $73,000 after purchasing an additional 55,000 shares during the last quarter. Institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.